298 related articles for article (PubMed ID: 22632108)
21. Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System.
Jung KS; Kim YJ; Kim YK; Park SK; Kim HG; Kim SJ; Park J; Choi CW; Do YR; Kim I; Park S; Mun YC; Jeong SH; Kim MK; Yi HG; Chang MH; Kim SY; Lee JH; Jang JH
Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):656-664. PubMed ID: 31375393
[TBL] [Abstract][Full Text] [Related]
22. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
[TBL] [Abstract][Full Text] [Related]
23. Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine.
Kim DY; Lee JH; Lee JH; Lee KH; Kim YK; Ahn JS; Kim HJ; Kim I; Yoon SS; Park S; Bae SH; Bang SM; Lee HG; Shin HJ; Lee JH; Min YH; Won JH; Mun YC; Oh D;
Ann Hematol; 2010 Jan; 89(1):15-23. PubMed ID: 19543727
[TBL] [Abstract][Full Text] [Related]
24. Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine.
Jabbour E; Garcia-Manero G; Ravandi F; Faderl S; O'Brien S; Fullmer A; Cortes JE; Wierda W; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):131-8. PubMed ID: 23260600
[TBL] [Abstract][Full Text] [Related]
25. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients.
Wijermans PW; Lübbert M; Verhoef G; Klimek V; Bosly A
Ann Hematol; 2005 Dec; 84 Suppl 1():9-17. PubMed ID: 16211386
[TBL] [Abstract][Full Text] [Related]
26. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
Joeckel TE; Lübbert M
Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063
[TBL] [Abstract][Full Text] [Related]
27. Increased PD-1/STAT1 ratio may account for the survival benefit in decitabine therapy for lower risk myelodysplastic syndrome.
Zhang Z; Chang CK; He Q; Guo J; Tao Y; Wu LY; Xu F; Wu D; Zhou LY; Su JY; Song LX; Xiao C; Li X
Leuk Lymphoma; 2017 Apr; 58(4):969-978. PubMed ID: 27686004
[TBL] [Abstract][Full Text] [Related]
28. [Expression of differentiation antigens on bone marrow myeloid cells of the patients with myelodysplastic syndromes and its clinical significances].
Li LJ; Fu R; Wang HQ; Yue LZ; Liu H; Wang J; Wang HL; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Song J; Wu YH; Xing LM; Guan J; Shao ZH
Zhonghua Yi Xue Za Zhi; 2010 Mar; 90(10):672-7. PubMed ID: 20450725
[TBL] [Abstract][Full Text] [Related]
29. The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine.
Miltiades P; Lamprianidou E; Vassilakopoulos TP; Papageorgiou SG; Galanopoulos AG; Kontos CK; Adamopoulos PG; Nakou E; Vakalopoulou S; Garypidou V; Papaioannou M; Hatjiharissi E; Papadaki HA; Spanoudakis E; Pappa V; Scorilas A; Tsatalas C; Kotsianidis I;
Clin Cancer Res; 2016 Apr; 22(8):1958-68. PubMed ID: 26700206
[TBL] [Abstract][Full Text] [Related]
30. Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories.
Falantes JF; Calderón C; Márquez Malaver FJ; Alonso D; Martín Noya A; Carrillo E; Martino ML; Montero I; González J; Parody R; Espigado I; Pérez-Simón JA
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):144-52. PubMed ID: 23137720
[TBL] [Abstract][Full Text] [Related]
31. Late hematological improvement of myelodysplastic syndrome following treatment with 5-azacitidine therapy.
Takaoka K; Hangaishi A; Ito A; Morioka T; Kida M; Usuki K
Intern Med; 2014; 53(19):2241-3. PubMed ID: 25274238
[TBL] [Abstract][Full Text] [Related]
32. Very-Low-Dose Decitabine Is Effective in Treating Intermediate- or High-Risk Myelodysplastic Syndrome.
Li H; Wang L; Wu Y; Su L; Zhao H; Zhang Y; Wang Z; Huang D; Huang Z; Wu X; Li X; Ye F; Yu F; Liu H; Wang JW; Cong J; Sun W; Chen HR; Wang J; Han B
Acta Haematol; 2017; 138(3):168-174. PubMed ID: 29045939
[TBL] [Abstract][Full Text] [Related]
33. Bone marrow blasts level predicts prognosis in patients with refractory cytopenia with multilineage dysplasia.
Wang H; Wang XQ; Xu XP; Lin GW
Eur J Haematol; 2009 Dec; 83(6):550-8. PubMed ID: 19737310
[TBL] [Abstract][Full Text] [Related]
34. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
Voso MT; Fenu S; Latagliata R; Buccisano F; Piciocchi A; Aloe-Spiriti MA; Breccia M; Criscuolo M; Andriani A; Mancini S; Niscola P; Naso V; Nobile C; Piccioni AL; D'Andrea M; D'Addosio A; Leone G; Venditti A
J Clin Oncol; 2013 Jul; 31(21):2671-7. PubMed ID: 23796988
[TBL] [Abstract][Full Text] [Related]
35. A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome.
Jeong SH; Kim YJ; Lee JH; Kim YK; Kim SJ; Park SK; Do YR; Kim I; Mun YC; Kim HG; Lee WS; Yi HG; Joo YD; Choi CW; Kim SR; Na SM; Jang JH
Oncotarget; 2015 Dec; 6(42):44985-94. PubMed ID: 26517692
[TBL] [Abstract][Full Text] [Related]
36. Benefits of hypomethylating therapy in IPSS lower-risk myelodysplastic syndrome patients: A retrospective multicenter case series study.
Lee JH; Kim YJ; Sohn SK; Yoon SS; Kim H; Cheong JW; Lee WS; Lee GW; Lim SN; Kim MK; Lee HS; Kim HJ;
Leuk Res; 2017 Sep; 60():135-144. PubMed ID: 28826063
[TBL] [Abstract][Full Text] [Related]
37. Wilms Tumor 1 (WT1) mRNA Expression Level at Diagnosis Is a Significant Prognostic Marker in Elderly Patients with Myelodysplastic Syndrome.
Nagasaki J; Aoyama Y; Hino M; Ido K; Ichihara H; Manabe M; Ohta T; Mugitani A
Acta Haematol; 2017; 137(1):32-39. PubMed ID: 27866185
[TBL] [Abstract][Full Text] [Related]
38. Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (Decitabine).
Lübbert M; Ihorst G; Sander PN; Bogatyreva L; Becker H; Wijermans PW; Suciu S; Bissé E; Claus R
Br J Haematol; 2017 Feb; 176(4):609-617. PubMed ID: 27905102
[TBL] [Abstract][Full Text] [Related]
39. Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer.
Generali D; Berruti A; Brizzi MP; Campo L; Bonardi S; Wigfield S; Bersiga A; Allevi G; Milani M; Aguggini S; Gandolfi V; Dogliotti L; Bottini A; Harris AL; Fox SB
Clin Cancer Res; 2006 Aug; 12(15):4562-8. PubMed ID: 16899602
[TBL] [Abstract][Full Text] [Related]
40. A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome.
Lee JH; Jang JH; Park J; Park S; Joo YD; Kim YK; Kim HG; Choi CW; Kim SH; Park SK; Park E; Min YH
Haematologica; 2011 Oct; 96(10):1441-7. PubMed ID: 21659363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
